Merck Turns To Outsourcing For Biosimilar Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck BioVentures has signed the CRO Parexel to assist in the development of biosimilars.
You may also be interested in...
Biosimilars: Nearly The End Already, Or Is The Best Yet To Come?
Sales of Europe's first round of biosimilars have been poor, prompting some to suggest they're dead before they really got started. Others claim biosimilars' true value will come with the next wave: biosimilar antibodies.
Biosimilars: Nearly The End Already, Or Is The Best Yet To Come?
Sales of Europe's first round of biosimilars have been poor, prompting some to suggest they're dead before they really got started. Others claim biosimilars' true value will come with the next wave: biosimilar antibodies.
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Merck is gearing up to test the new regulatory pathway for biosimilar drugs in the U.S. and is hoping to be the first drug maker to move a biologic through the abbreviated process, Merck BioVentures President Michael Kamarck said in an interview June 28